CRISPR/Cas9 drug
Evidence from:
primary |
all sources
Related entities (2)
| Subject | Relation | Object | p-value | Evidence |
|---|---|---|---|---|
| CRISPR/Cas9 | targets | Kcnj6 | — | 1 |
| CRISPR/Cas9 | targets | OPRM1 A118G | — | 1 |
Mentioned in (11)
Papers in which this entity is mentioned.
- ConSeqUMI, an error-free nanopore sequencing pipeline to identify and extract individual nucleic acid molecules from heterogeneous samples. (2025)
- Functional analysis of cancer-associated germline risk variants. (2025)
- ConSeqUMI, an error-free nanopore sequencing pipeline to identify and extract individual nucleic acid molecules from heterogeneous samples. (2025)
- Alcohol reverses the effects of KCNJ6 (GIRK2) noncoding variants on excitability of human glutamatergic neurons. (2023)
- Novel Ethanol-Sensitive Mutants Identified in an F3 Forward Genetic Screen. (2020)
- Diverse noncoding mutations contribute to deregulation of cis-regulatory landscape in pediatric cancers. (2020)
- Reciprocal monoallelic expression of ASAR lncRNA genes controls replication timing of human chromosome 6. (2020)
- Differential sensitivity of human neurons carrying μ opioid receptor (MOR) N40D variants in response to ethanol. (2020)
- Alternative Lengthening of Telomeres through Two Distinct Break-Induced Replication Pathways. (2019)
- MutationalPatterns: comprehensive genome-wide analysis of mutational processes. (2018)
- MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. (2014)
Merged raw entities (1)
All extracted name/type variants the normalize job merged into this entity. Use this to spot wrong merges, or aliases that should be split off.
| Raw name | Type | Papers | Mentions |
|---|---|---|---|
| crispr/cas9 | drug | 22 | 44 |